Positive News SentimentPositive NewsNASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $4.13 -0.11 (-2.59%) Closing price 04:00 PM EasternExtended Trading$4.12 0.00 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexeo Therapeutics Stock (NASDAQ:LXEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lexeo Therapeutics alerts:Sign Up Key Stats Today's Range$4.11▼$4.4850-Day Range$4.21▼$6.9152-Week Range$3.60▼$10.99Volume487,746 shsAverage Volume921,244 shsMarket Capitalization$324.29 millionP/E RatioN/ADividend YieldN/APrice Target$20.14Consensus RatingModerate Buy Company Overview Lexeo Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders. The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings. To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy. Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide. AI Generated. May Contain Errors. Read More Lexeo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreLXEO MarketRank™: Lexeo Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 718th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingLexeo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLexeo Therapeutics has a consensus price target of $20.14, representing about 386.0% upside from its current price of $4.15.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.23) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.53% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 17.36, which indicates bearish sentiment.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 4.26%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentLexeo Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lexeo Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for LXEO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $336,462.00 in company stock.Percentage Held by Insiders5.30% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXEO Stock News HeadlinesLexeo Therapeutics (NASDAQ:LXEO) CEO Sells $16,910.52 in StockMay 21, 2026 | insidertrades.comLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceMay 19, 2026 | globenewswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 10 at 1:00 AM | Porter & Company (Ad)LXEO Share News TodayMay 16, 2026 | uk.investing.comLexeo Highlights Q1 Progress Advancing Cardiac Gene TherapiesMay 11, 2026 | tipranks.comLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | globenewswire.comLexeo Therapeutics Adds Genomic Medicine Leader to BoardApril 30, 2026 | tipranks.comLexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026April 27, 2026 | quiverquant.comQSee More Headlines LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $9.93 at the beginning of 2026. Since then, LXEO shares have decreased by 58.3% and is now trading at $4.1450. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $127 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at a price of $13.00-$15.00 per share. Who are Lexeo Therapeutics' major shareholders? Lexeo Therapeutics' top institutional investors include Affinity Asset Advisors LLC (6.43%), Janus Henderson Group PLC (6.34%), Orbimed Advisors LLC (4.59%) and ADAR1 Capital Management LLC (1.87%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Jose Manuel Otero, Eric Adler and Tai Sandi See. View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexeo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/11/2026Today6/10/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 4 weeks, LXEO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year Founded2018Price Target and Rating Average Price Target for Lexeo Therapeutics$20.14 High Price Target$30.00 Low Price Target$10.00 Potential Upside/Downside+387.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$99.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.48% Return on Assets-41.72% Debt Debt-to-Equity RatioN/A Current Ratio14.16 Quick Ratio14.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book1.22Miscellaneous Outstanding Shares78,520,000Free Float74,360,000Market Cap$324.29 million OptionableNot Optionable Beta1.38 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LXEO) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredThe part that convinced me Joel is legitMost trading gurus cite big win rates but won't let you verify them. Joel Peterson is different - his trade pl...Crypto Swap Profits | SponsoredForbes calls this a "golden era" for retirement incomeForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXEO Stock Alerts